Fiasp (Insulin Aspart) for Diabetes

Overview
Fiasp is a rapid-acting insulin analog approved by the U.S. Food and Drug Administration (FDA) to help improve blood glucose (sugar) control in adults and children with diabetes mellitus. Fiasp is indicated for individuals who require rapid insulin action around mealtime to manage blood glucose levels, and it is typically used alongside an intermediate- or long-acting insulin for comprehensive blood glucose management. Fiasp is also known by its drug name, insulin aspart.

Fiasp works by helping to reduce blood sugar levels quickly after meals. It begins acting in the body shortly after injection, mimicking the natural insulin spike that occurs when a person eats. This rapid action helps to prevent blood sugar spikes following meals in individuals with diabetes.

How do I take it?
Prescribing information states that Fiasp is typically administered as a subcutaneous (under the skin) injection at the start of a meal or within 20 minutes after beginning a meal. Injection sites include the abdomen, upper arm, or thigh, and users are advised to rotate injection sites within the same region to lower the risk of localized skin changes. Fiasp may also be used in an insulin pump for continuous subcutaneous infusion according to the pump manufacturer’s guidelines. For intravenous infusion, Fiasp should only be administered under medical supervision after dilution. Always use Fiasp exactly as prescribed by your health care provider.

Side effects
Common side effects of Fiasp include hypoglycemia (low blood sugar), allergic reactions, sensitivity at the injection or infusion site, lipodystrophy (skin thickening or lumps) at the injection site, and weight gain.

Rare but serious side effects may include severe hypoglycemia (very low blood sugar), hypokalemia (dangerously low potassium levels), severe allergic reactions including anaphylaxis, fluid retention that may lead to heart failure (especially when used with thiazolidinediones), and diabetic ketoacidosis if there is a malfunction with an insulin pump device.

For more information about this treatment, visit:

Label: Fiasp — Insulin Aspart Injection Injection, Solution; Fiasp — Insulin Aspart Injection, Solution — DailyMed